Research Analysts Offer Predictions for AXSM Q4 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Stock analysts at HC Wainwright reduced their Q4 2027 EPS estimates for Axsome Therapeutics in a research report issued on Monday, August 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $2.53 for the quarter, down from their previous forecast of $2.81. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.78) per share.

Other research analysts have also recently issued research reports about the company. Guggenheim raised their target price on Axsome Therapeutics from $260.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. TD Cowen boosted their price target on shares of Axsome Therapeutics from $275.00 to $300.00 and gave the stock a “buy” rating in a research report on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft set a $280.00 price target on shares of Axsome Therapeutics in a report on Tuesday, May 5th. Oppenheimer set a $280.00 price objective on shares of Axsome Therapeutics in a research report on Monday, May 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $267.60.

Axsome Therapeutics Stock Down 1.1%

Shares of AXSM stock opened at $205.40 on Tuesday. Axsome Therapeutics has a 1 year low of $112.90 and a 1 year high of $260.19. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.34 and a current ratio of 1.43. The business’s fifty day moving average is $231.17 and its 200-day moving average is $206.29. The stock has a market cap of $10.76 billion, a PE ratio of -54.77 and a beta of 0.65.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Monday, August 10th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.10). The firm had revenue of $218.38 million for the quarter, compared to the consensus estimate of $221.11 million. Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%.

Insider Transactions at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 33,000 shares of Axsome Therapeutics stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $240.09, for a total transaction of $7,922,970.00. Following the completion of the sale, the chief financial officer owned 42,867 shares of the company’s stock, valued at approximately $10,291,938.03. This trade represents a 43.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark Coleman sold 643 shares of the business’s stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $249.00, for a total value of $160,107.00. Following the completion of the sale, the director directly owned 30,389 shares of the company’s stock, valued at approximately $7,566,861. The trade was a 2.07% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 200,766 shares of company stock worth $46,685,646. 20.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AXSM. Kemnay Advisory Services Inc. acquired a new position in Axsome Therapeutics during the fourth quarter worth $31,000. Hollencrest Capital Management lifted its position in shares of Axsome Therapeutics by 400.0% in the first quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock worth $34,000 after buying an additional 160 shares during the last quarter. Ameriflex Group Inc. acquired a new stake in shares of Axsome Therapeutics in the fourth quarter worth about $37,000. ABS Investment Management LLC bought a new stake in shares of Axsome Therapeutics during the 2nd quarter worth about $171,339,000. Finally, Silvant Capital Management LLC bought a new position in shares of Axsome Therapeutics in the second quarter valued at approximately $66,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.